Bio-Path Holdings, Inc.
BPTH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133818
No open-market purchases or sales by Bio-Path Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Bio-Path Holdings, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 23 | 19 | −4 |
| Shares | 694.3K | 597.1K | −97.2K (−14.0%) |
| Value | $256.6K | $276.5K | +$19.8K (+7.7%) |
New holders (3)
Institutions that held Bio-Path Holdings, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 24,195 | $11.2K | 0.00% |
| UBS Group AG | 22,788 | $10.6K | 0.00% |
| Allworth Financial LP | 150 | $70 | 0.00% |
Sold out (7)
Institutions that held Bio-Path Holdings, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Walleye Capital LLC | 209,238 | $77.4K |
| Renaissance Technologies LLC | 23,300 | $9.00K |
| Warberg Asset Management LLC | 24,000 | $8.88K |
| Millennium Management LLC | 18,571 | $6.87K |
| Crewe Advisors LLC | 70 | $26 |
| JPMorgan Chase & Co | 8 | $3 |
| McClarren Financial Advisors, Inc. | 1 | $0 |